| Identification | Back Directory | [Name]
4-Acridinecarboxamide, N-[6-(hydroxyamino)-6-oxohexyl]- | [CAS]
1620054-84-3 | [Synonyms]
WJ35435
WJ-35435
WJ 35435
4-Acridinecarboxamide, N-[6-(hydroxyamino)-6-oxohexyl]- | [Molecular Formula]
C20H21N3O3 | [MOL File]
1620054-84-3.mol | [Molecular Weight]
351.4 |
| Hazard Information | Back Directory | [Description]
WJ35435 is a dual inhibitor of histone deacetylase and topoisomerase I. | [Uses]
WJ35435 is a dual-targeted anticancer hybrid that induces anti-HDAC (in particular HDAC1 and HDAC6) and anti-topoisomerase I activities that causes DNA damage associated with a low DNA repair capability and induces cell cycle arrest at G1- and G2-phase to apoptosis. WJ35435 induces histone H3 acetylation and phosphorylation, α-tubulin acetylation and γ-H2AX formation to achieve anti-HDAC effect. WJ35435 is promising for research of cancer[1]. | [References]
[1] Yu C C, et al. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I[J]. Biochemical pharmacology, 2014, 90(3): 320-330. DOI:10.1016/j.bcp.2014.06.001 |
|
|